Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Nov;40(11):2494–2499. doi: 10.1128/aac.40.11.2494

Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy.

J M Prins 1, G J Weverling 1, K de Blok 1, R J van Ketel 1, P Speelman 1
PMCID: PMC163563  PMID: 8913452

Abstract

There is no established dosing schedule for once-daily aminoglycoside dosing regimens, and accepted guidelines for monitoring therapy are lacking. We derived a simplified schedule from the Hull and Sarubbi (J. H. Hull and F. A. Sarubbi, Ann. Intern. Med. 85:183-189, 1976) nomogram, for which efficacy and safety in a once-daily dosing regimen were previously demonstrated, and prospectively followed serum aminoglycoside levels in patients. The standard treatment was gentamicin or tobramycin at 4 mg/kg of body weight given intravenously once daily. When the renal function was decreased, the daily dose was reduced, as follows: for an estimated creatinine clearance of between 50 and 80 ml/min, the daily dose was 3.25 mg/kg, for an estimated creatinine clearance of between 30 and 50 ml/min, the daily dose was 2.5 mg/kg, and for an estimated creatinine clearance of below 30 ml/min, the daily dose was 2 mg/kg. A total of 221 patients were studied (184 received gentamicin and 37 received tobramycin). First trough levels above 2 mg/liter were recorded in 11% of the patients, and they all had a baseline creatinine clearance below 50 ml/min, or a substantial decrease in clearance between enrollment and the day that the trough level was obtained. A peak level below 6 mg/liter was recorded in 6% of the patients, and half of them received the lowest daily dose. Twenty-five of the 179 evaluable patients (14%; 95% confidence interval, 9 to 19%) fulfilled the criteria for nephrotoxicity. In a multiple regression analysis, the duration of treatment and the use of other nephrotoxic antibiotics or high-dose furosemide, but not trough levels, were significant risk factors. Since the meaning of low peak levels is unclear and since most studies with multiple daily regimens confirm the lack of an association between trough levels and toxicity, we believe that monitoring of serum drug levels can be restricted to monitoring of trough levels in patients with a creatinine clearance below 50 ml/min or with a deteriorating renal function.

Full Text

The Full Text of this article is available as a PDF (180.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adelman R. D., Spangler W. L., Beasom F., Ishizaki G., Conzelman G. M. Furosemide enhancement of experimental gentamicin nephrotoxicity: comparison of functional and morphological changes with activities of urinary enzymes. J Infect Dis. 1979 Sep;140(3):342–352. doi: 10.1093/infdis/140.3.342. [DOI] [PubMed] [Google Scholar]
  2. Barza M., Ioannidis J. P., Cappelleri J. C., Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ. 1996 Feb 10;312(7027):338–345. doi: 10.1136/bmj.312.7027.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Beaubien A. R., Desjardins S., Ormsby E., Bayne A., Carrier K., Cauchy M. J., Henri R., Hodgen M., Salley J., St Pierre A. Incidence of amikacin ototoxicity: a sigmoid function of total drug exposure independent of plasma levels. Am J Otolaryngol. 1989 Jul-Aug;10(4):234–243. doi: 10.1016/0196-0709(89)90002-1. [DOI] [PubMed] [Google Scholar]
  4. Bertino J. S., Jr, Booker L. A., Franck P. A., Jenkins P. L., Franck K. R., Nafziger A. N. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis. 1993 Jan;167(1):173–179. doi: 10.1093/infdis/167.1.173. [DOI] [PubMed] [Google Scholar]
  5. Blaser J., König C., Simmen H. P., Thurnheer U. Monitoring serum concentrations for once-daily netilmicin dosing regimens. J Antimicrob Chemother. 1994 Feb;33(2):341–348. doi: 10.1093/jac/33.2.341. [DOI] [PubMed] [Google Scholar]
  6. Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
  7. Goetz M. B., Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J Antimicrob Chemother. 1993 Aug;32(2):325–334. doi: 10.1093/jac/32.2.325. [DOI] [PubMed] [Google Scholar]
  8. Hull J. H., Sarubbi F. A., Jr Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med. 1976 Aug;85(2):183–189. doi: 10.7326/0003-4819-85-2-183. [DOI] [PubMed] [Google Scholar]
  9. Kahlmeter G., Dahlager J. I. Aminoglycoside toxicity - a review of clinical studies published between 1975 and 1982. J Antimicrob Chemother. 1984 Jan;13 (Suppl A):9–22. doi: 10.1093/jac/13.suppl_a.9. [DOI] [PubMed] [Google Scholar]
  10. Lesar T. S., Rotschafer J. C., Strand L. M., Solem L. D., Zaske D. E. Gentamicin dosing errors with four commonly used nomograms. JAMA. 1982 Sep 10;248(10):1190–1193. [PubMed] [Google Scholar]
  11. Maller R., Ahrne H., Holmen C., Lausen I., Nilsson L. E., Smedjegård J. Once- versus twice-daily amikacin regimen: efficacy and safety in systemic gram-negative infections. Scandinavian Amikacin Once Daily Study Group. J Antimicrob Chemother. 1993 Jun;31(6):939–948. doi: 10.1093/jac/31.6.939. [DOI] [PubMed] [Google Scholar]
  12. Mattie H., Craig W. A., Pechère J. C. Determinants of efficacy and toxicity of aminoglycosides. J Antimicrob Chemother. 1989 Sep;24(3):281–293. doi: 10.1093/jac/24.3.281. [DOI] [PubMed] [Google Scholar]
  13. McCormack J. P., Jewesson P. J. A critical reevaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis. 1992 Jan;14(1):320–339. doi: 10.1093/clinids/14.1.320. [DOI] [PubMed] [Google Scholar]
  14. Moore R. D., Lietman P. S., Smith C. R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987 Jan;155(1):93–99. doi: 10.1093/infdis/155.1.93. [DOI] [PubMed] [Google Scholar]
  15. Moore R. D., Smith C. R., Lietman P. S. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. doi: 10.1016/0002-9343(84)90358-9. [DOI] [PubMed] [Google Scholar]
  16. Moore R. D., Smith C. R., Lietman P. S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis. 1984 Mar;149(3):443–448. doi: 10.1093/infdis/149.3.443. [DOI] [PubMed] [Google Scholar]
  17. Nakahama H., Fukuhara Y., Orita Y., Yamauchi A., Takama T., Kamada T. Furosemide accelerates gentamicin accumulation in cultured renal cells (LLC-PK1 cells). Nephron. 1989;53(2):138–141. doi: 10.1159/000185726. [DOI] [PubMed] [Google Scholar]
  18. Nicolau D. P., Freeman C. D., Belliveau P. P., Nightingale C. H., Ross J. W., Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995 Mar;39(3):650–655. doi: 10.1128/AAC.39.3.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Prins J. M., Büller H. R., Kuijper E. J., Tange R. A., Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet. 1993 Feb 6;341(8841):335–339. doi: 10.1016/0140-6736(93)90137-6. [DOI] [PubMed] [Google Scholar]
  20. Prins J. M., Koopmans R. P., Büller H. R., Kuijper E. J., Speelman P. Easier monitoring of aminoglycoside therapy with once-daily dosing schedules. Eur J Clin Microbiol Infect Dis. 1995 Jun;14(6):531–535. doi: 10.1007/BF02113434. [DOI] [PubMed] [Google Scholar]
  21. Rozdzinski E., Kern W. V., Reichle A., Moritz T., Schmeiser T., Gaus W., Kurrle E. Once-daily versus thrice-daily dosing of netilmicin in combination with beta-lactam antibiotics as empirical therapy for febrile neutropenic patients. J Antimicrob Chemother. 1993 Apr;31(4):585–598. doi: 10.1093/jac/31.4.585. [DOI] [PubMed] [Google Scholar]
  22. Sawyers C. L., Moore R. D., Lerner S. A., Smith C. R. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis. 1986 Jun;153(6):1062–1068. doi: 10.1093/infdis/153.6.1062. [DOI] [PubMed] [Google Scholar]
  23. Schentag J. J., Cerra F. B., Plaut M. E. Clinical and pharmacokinetic characteristics of aminoglycoside nephrotoxicity in 201 critically ill patients. Antimicrob Agents Chemother. 1982 May;21(5):721–726. doi: 10.1128/aac.21.5.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Smith C. R., Lipsky J. J., Laskin O. L., Hellmann D. B., Mellits E. D., Longstreth J., Lietman P. S. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med. 1980 May 15;302(20):1106–1109. doi: 10.1056/NEJM198005153022002. [DOI] [PubMed] [Google Scholar]
  25. Sturm A. W. Netilmicin in the treatment of gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis. 1989 May;159(5):931–937. doi: 10.1093/infdis/159.5.931. [DOI] [PubMed] [Google Scholar]
  26. Vogelman B., Gudmundsson S., Leggett J., Turnidge J., Ebert S., Craig W. A. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis. 1988 Oct;158(4):831–847. doi: 10.1093/infdis/158.4.831. [DOI] [PubMed] [Google Scholar]
  27. Zaske D. E., Cipolle R. J., Rotschafer J. C., Solem L. D., Mosier N. R., Strate R. G. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982 Mar;21(3):407–411. doi: 10.1128/aac.21.3.407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. de Vries P. J., Verkooyen R. P., Leguit P., Verbrugh H. A. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis. 1990 Mar;9(3):161–168. doi: 10.1007/BF01963832. [DOI] [PubMed] [Google Scholar]
  29. ter Braak E. W., de Vries P. J., Bouter K. P., van der Vegt S. G., Dorrestein G. C., Nortier J. W., van Dijk A., Verkooyen R. P., Verbrugh H. A. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med. 1990 Jul;89(1):58–66. doi: 10.1016/0002-9343(90)90099-y. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES